(1442) NGS-Based MRD Assessment Refines Prognostication After Venetoclax-Based First-Line Combinations for Chronic Lymphocytic Leukemia: A Prospective Analysis of the Phase 3 GAIA/CLL13 Trial

Primary Author / Presenter(s)

• MF

  Moritz Fürstenau, MD

  Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne
  Cologne, Germany